History
We are committed to restore and improve the lives of
suffering patients by delivering novel therapeutic solutions.
-
2026
- Series E(KRW 9.5 billion) closed
- Korea Drug Development Funding
- ICM-203 Ph1/2a (AU) LPLV completed
- ICM-203 Ph1/2a (AU) CSR completed
-
2025
- Completed patient enrollment for Australian clinical trial (ICM-203)
-
2024
- Korea Drug Development Funding
- ICM-502 Licensing Out(Global Pharma)
-
2023
- Completed Cohort 1 patient enrollment for Australian clinical trial (ICM-203)
-
2022
- ICM-203 FDA P1/2a IND approval
- Initiated Phase 1/2a patient dosing for ICM203 in Australia
-
2021
- Pre-IPO (KRW 21 billion) closed
- Initiated Phase1/2a global clinical trial for ICM-203
-
2020
- Completion of ICM-203 GMP Production
- Completion of ICM-203 GLP Toxicology/Biodistribution Study
- Established ICM Biotech Australia Pty Ltd
- Winner of Yonsei University
Grand-Prize for Faculty Start-up
-
2019
- Series C (KRW 20.1 billion) closed
-
2018
- Qualified as a Military Service Designation Company by Ministry of National Defense
-
2017
- Series B (KRW 6 billion) closed
-
2016
- Series A (KRW 5 billion) closed
- Venture Company Certification by Korea Venture Capital Association
-
2015
- Corporate R&D Center
Certification from KOITA
- Corporate R&D Center
-
2012
- Industry-Academy Joint-Venture Support Program (Ministry of Education and Science Technology)
- Establishment of ICM Co., Ltd.
- New Drug Candidate Optimization Support Program (Ministry of Science, ICT and Future Planning)